|
David Standring, Ph.D., has served as senior vice president of biology at Idenix Pharmaceuticals, Inc. since March 2006. Dr. Standring joined Idenix in 2000 as executive director of research and development and became vice president, biology in May 2002. Before joining Idenix, Dr. Standring was affiliated with Schering Plough Research Institute as an associate director of virology. Prior to that position he was with Bristol-Myers Squibb Pharmaceutical Research Institute as group leader of hepatitis, where he was responsible for hepatitis research programs leading to the filing of Investigational New Drug (IND) applications and subsequent clinical development of several hepatitis drug candidates. Before entering the pharmaceutical industry, Dr. Standring was assistant professor at the University of California at San Francisco where he pioneered groundbreaking research describing the assembly and replication of the hepatitis B virus. Dr. Standring holds a Ph.D. in bioorganic chemistry from Harvard University and a bachelor’s and master’s degree in chemistry from St. John’s College at the University of Oxford. | 